Amundi Lowers Stock Holdings in Encompass Health Corporation $EHC

Amundi lowered its position in Encompass Health Corporation (NYSE:EHC - Free Report) by 3.9% during the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 184,760 shares of the company's stock after selling 7,512 shares during the period. Amundi owned 0.18% of Encompass Health worth $18,822,000 as of its most recent SEC filing.

Several other hedge funds have also bought and sold shares of EHC. Invesco Ltd. grew its holdings in Encompass Health by 5.1% during the first quarter. Invesco Ltd. now owns 5,818,783 shares of the company's stock worth $589,326,000 after buying an additional 282,532 shares in the last quarter. T. Rowe Price Investment Management Inc. increased its position in shares of Encompass Health by 25.6% during the 1st quarter. T. Rowe Price Investment Management Inc. now owns 2,080,918 shares of the company's stock valued at $210,756,000 after purchasing an additional 424,691 shares during the last quarter. Dimensional Fund Advisors LP raised its stake in shares of Encompass Health by 5.3% during the 1st quarter. Dimensional Fund Advisors LP now owns 1,871,581 shares of the company's stock worth $189,549,000 after purchasing an additional 93,992 shares during the period. Price T Rowe Associates Inc. MD boosted its holdings in shares of Encompass Health by 13.1% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 1,822,376 shares of the company's stock worth $184,571,000 after buying an additional 211,707 shares during the last quarter. Finally, Fuller & Thaler Asset Management Inc. grew its position in Encompass Health by 11.9% during the first quarter. Fuller & Thaler Asset Management Inc. now owns 1,541,477 shares of the company's stock valued at $156,121,000 after buying an additional 163,400 shares during the period. Institutional investors and hedge funds own 97.25% of the company's stock.

Encompass Health Price Performance

Shares of EHC traded down $0.24 during midday trading on Friday, hitting $126.57. 272,365 shares of the company traded hands, compared to its average volume of 802,624. Encompass Health Corporation has a one year low of $87.85 and a one year high of $127.15. The firm has a market cap of $12.75 billion, a P/E ratio of 24.76, a PEG ratio of 2.18 and a beta of 0.92. The company has a debt-to-equity ratio of 0.76, a current ratio of 1.06 and a quick ratio of 1.06. The stock has a 50-day moving average of $117.36 and a 200-day moving average of $112.58.

Encompass Health (NYSE:EHC - Get Free Report) last issued its quarterly earnings data on Monday, August 4th. The company reported $1.40 EPS for the quarter, beating the consensus estimate of $1.20 by $0.20. Encompass Health had a net margin of 9.22% and a return on equity of 17.83%. The company had revenue of $1.46 billion during the quarter, compared to analysts' expectations of $1.43 billion. During the same quarter in the previous year, the company earned $1.11 earnings per share. Encompass Health's revenue for the quarter was up 12.0% on a year-over-year basis. Encompass Health has set its FY 2025 guidance at 5.120-5.340 EPS. As a group, sell-side analysts predict that Encompass Health Corporation will post 4.8 EPS for the current fiscal year.

Encompass Health Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, October 15th. Shareholders of record on Wednesday, October 1st will be issued a $0.19 dividend. This represents a $0.76 annualized dividend and a dividend yield of 0.6%. The ex-dividend date of this dividend is Wednesday, October 1st. This is an increase from Encompass Health's previous quarterly dividend of $0.17. Encompass Health's payout ratio is 13.31%.

Insider Activity

In other news, EVP Patrick William Tuer sold 1,020 shares of the business's stock in a transaction dated Wednesday, August 27th. The stock was sold at an average price of $123.59, for a total transaction of $126,061.80. Following the completion of the transaction, the executive vice president owned 18,846 shares of the company's stock, valued at approximately $2,329,177.14. The trade was a 5.13% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 2.00% of the company's stock.

Analysts Set New Price Targets

Several analysts have commented on the stock. UBS Group lifted their price objective on shares of Encompass Health from $130.00 to $140.00 and gave the stock a "buy" rating in a research report on Wednesday, August 6th. Stephens upgraded Encompass Health from an "overweight" rating to a "strong-buy" rating and set a $135.00 price objective on the stock in a research note on Thursday, June 5th. Wall Street Zen lowered Encompass Health from a "strong-buy" rating to a "buy" rating in a report on Friday, June 6th. Bank of America boosted their target price on Encompass Health from $145.00 to $160.00 and gave the company a "buy" rating in a research note on Wednesday. Finally, KeyCorp increased their price target on Encompass Health from $122.00 to $135.00 and gave the stock an "overweight" rating in a research note on Tuesday, May 27th. One investment analyst has rated the stock with a Strong Buy rating and seven have issued a Buy rating to the company. According to data from MarketBeat, the company has an average rating of "Buy" and an average price target of $137.71.

Encompass Health Profile

Encompass Health Corporation provides post-acute healthcare services in the United States and Puerto Rico. It owns and operates inpatient rehabilitation hospitals that provide medical, nursing, therapy, and ancillary services. The company provides specialized rehabilitative treatment on an inpatient basis to patients who have experienced physical or cognitive disabilities or injuries due to medical conditions, such as strokes, hip fractures, and various debilitating neurological conditions.